Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis

Int J Rheum Dis. 2020 Apr;23(4):582-588. doi: 10.1111/1756-185X.13805. Epub 2020 Feb 26.

Abstract

Aim: Positron emission tomography/computed tomography (PET/CT) can detect cranial and large vessel inflammation in giant cell arteritis (GCA). We aimed to determine the change and significance of vascular activity at diagnosis and 6 months.

Method: Newly diagnosed GCA patients underwent time-of-flight fluorine-18-fluoro-2-deoxyglucose PET/CT from vertex to diaphragm within 72 hours of commencing corticosteroids and were followed for 12 months. A 6 months scan was performed in patients with inflammatory features on biopsy or CT aortitis. Vascular uptake was visually graded by 2 blinded readers across 18 artery segments from 0 (no increased uptake) to 3 (very marked uptake). Scores were summed to give a total vascular score (TVS).

Results: We enrolled 21 GCA patients and 15 underwent the serial scan. Twelve (57%) patients experienced a relapse and 5 of these had ischemic features of vision disturbance, jaw or limb claudication. The median TVS fell from 14 (interquartile range [IQR] 4-24) at baseline to 5 (IQR 0-10) at 6 months (P < .01) with reduction in both cranial and large artery scores. While the overall relapse rate was similar between patients with a high (≥10) and low baseline TVS, patients with high scores were numerically more likely to experience an ischemic relapse (33% vs 11%, P = .34). Five out of 15 patients had persistent uptake in at least 1 vessel on the serial PET/CT but none experienced a subsequent relapse.

Conclusion: Vascular activity decreased in cranial and large arteries between diagnosis and 6 months. Persistent activity did not predict subsequent relapse.

Keywords: giant cell arteritis; positron emission tomography; prognosis; systemic vasculitis.

Publication types

  • Multicenter Study

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage
  • Giant Cell Arteritis / diagnostic imaging*
  • Giant Cell Arteritis / drug therapy
  • Humans
  • Male
  • New South Wales
  • Positron Emission Tomography Computed Tomography*
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals / administration & dosage
  • Recurrence
  • Time Factors
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18

Grants and funding